SCHEMBL2126752

SCHEMBL2126752

COC(=O)Cc1ccc(O)c(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.60
GAA P10253 2/20 0.60
GFER P55789 1/20 0.60
APP P05067 2/20 0.49
HSP90AB1 P08238 1/20 0.49
PDK2 Q15119 1/20 0.48
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
LMNA P02545 1/20 0.43
TSHR P16473 2/20 0.43
NFKB1 P19838 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
YWHAG P61981 1/20 0.42
P4HB P07237 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SLC7A5 Q01650 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20598923 0.86 ALDH1A1 (0.62) ALDH1A1GAAGFERHSP90AB1PDK2
SCHEMBL20214473 0.84 GAA (0.49) ALDH1A1GAAGFERHSP90AB1PDK2
SCHEMBL2642622 0.84 ALDH1A1 (0.49) ALDH1A1GAAGFERHSP90AB1PDK2
SCHEMBL1780814 0.83 IDO1 (0.53) ALDH1A1GAAGFERPDK2CYP4F2
SCHEMBL20576241 0.83 ALDH1A1 (0.48) ALDH1A1GAAGFERHSP90AB1PDK2
SCHEMBL20502317 0.83 ALDH1A1 (0.46) ALDH1A1GAAGFERAPPPDK2
SCHEMBL2645838 0.81 ALDH1A1 (0.49) ALDH1A1GAAGFERHSP90AB1PDK2
SCHEMBL8448707 0.81 ALDH1A1 (0.46) ALDH1A1GAAGFERHSP90AB1PDK2
SCHEMBL8448706 0.81 GAA (0.46) ALDH1A1GAAGFERHSP90AB1PDK2
SCHEMBL20214462 0.81 ALDH1A1 (0.46) ALDH1A1GAAGFERHSP90AB1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392367-B2 IRE1 small molecule inhibitors QUENTIS THERAPEUTICS, INC. (US) 2019-08-27 US disclosed
US-10392367-B2 IRE1 small molecule inhibitors QUENTIS THERAPEUTICS, INC. (US) 2019-08-27 US disclosed
WO-2018222917-A1 IRE1 SMALL MOLECULE INHIBITORS QUENTIS THERAPEUTICS, INC. (US) 2018-12-06 WO disclosed
US-20180346447-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2018-12-06 US disclosed
US-20120289520-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2012-11-15 US disclosed
US-20120289520-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2012-11-15 US disclosed
US-20120289520-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2012-11-15 US disclosed
CN-102498103-A Pyrazine carboxamides as DGAT1 inhibitors ASTRAZENECA AB 2012-06-13 CN disclosed
US-8188092-B2 Substituted pyrazines as DGAT-1 inhibitors ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188092-B2 Substituted pyrazines as DGAT-1 inhibitors ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188092-B2 Substituted pyrazines as DGAT-1 inhibitors ASTRAZENECA AB (SE) 2012-05-29 US disclosed
EP-2443096-A1 PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 AstraZeneca AB (SE) 2012-04-25 EP disclosed
US-20100324068-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2010-12-23 US disclosed
US-20100324068-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2010-12-23 US disclosed
US-20100324068-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2010-12-23 US disclosed
WO-2010146395-A1 PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 ASTRAZENECA AB (SE) 2010-12-23 WO disclosed
WO-2010146395-A1 PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 ASTRAZENECA AB (SE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10392367-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 ALDH1A1 3482/4885GAA 1747/4885GFER 3621/4885
US-20100324068-A1 CHEMICAL COMPOUNDS 785 GPBAR1, DGAT1, GPR119 ALDH1A1 699/4885GAA 200/4885GFER 2761/4885
US-20180346447-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 ALDH1A1 3482/4885GAA 1747/4885GFER 3621/4885
US-20120289520-A1 CHEMICAL COMPOUNDS 785 DGAT1, DGAT2, SLC5A1 ALDH1A1 208/4885GAA 46/4885GFER 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.